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SIRNA THERAPY IN GLIOBLASTOMA STEM CELLS: IDENTIFICATION OF 
TARGET GENES AND POTENTIAL THERAPEUTIC IMPLICATIONS. Benjamin T. 
Himes, Jiangbing Zhou, Toral Patel, Marie-Aude Guie, Michael Wyler, Joseph M. 
Piepmeier, W. Mark Saltzman, Department of Biomedical Engineering, Yale University, 
New Haven, CT. 
 
Glioblastoma multiforme (GBM), the most common primary brain malignancy, carries a 
grim prognosis; survival statistics have scarcely improved in decades. Even with the 
development of temozolomide, the current front-line chemotherapeutic agent for GBM, 
improvement in long-term survival has been minimal, with recurrence virtually assured. One 
explanation for the persistence of this disease is the presence of a stem-like cell population 
within GBM (glioblastoma stem cells, or GSCs). These cells are capable of self-renewal, 
tumor initiation, and are resistant to chemotherapy. We hypothesized that derangement in the 
expression of genes critical for the maintenance of GSCs could eliminate these cells outright, 
or induce sufficient cell differentiation to sensitize them to existing chemotherapeutic agents. 
To this end we performed a genome-wide small interfering RNA (siRNA) screen in search of 
genes that, when reduced in expression, cause GSC cell death or induce differentiation as 
measured by changes in nestin expression or cell morphology. Our screening yielded a 
number of candidate siRNAs: their efficacy in reducing cell viability was demonstrated 
across a number of genetically distinct GSC cell lines. We further identified two siRNAs, 
targeting ubiquitin C (UBC) and disheveled 2 (DVL2), respectively, that significantly 
sensitize GSCs to the effects of temozolomide (p<0.05). A similar but not significant effect 
was also observed in combination treatment with siRNA and either paclitaxel or doxorubicin. 
We conclude from these observations that siRNA-mediated gene knockdown presents a 
promising avenue in the development of novel treatments for GBM by taking into account 
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With approximately 15,000 new diagnoses in the United States annually, 
glioblastoma multiforme (GBM) represents the most common adult brain malignancy (1). 
With this diagnosis comes an exceedingly poor prognosis. Surgical resection of as large a 
volume of tumor as possible, combined additional treatment with radiosurgery and 
temozolomide chemotherapy, modestly improve survival, but overall 5-year survival stands 
under 4% (2, 3). Median survival statistics are similarly grim, with most patients living just 
beyond a year following diagnosis (3, 4). While predominately found in older patients 
(median age at diagnosis is 65), GBM occurs in all adult age groups, and risk factors are 
poorly defined, with little evidence for family history or environmental exposures playing a 
role in disease development (1, 5). Disease recurrence is all but assured given the infiltrative 
nature of GBM, which penetrates the surrounding brain parenchyma and prevents total 
resection (3). 
It is with this knowledge in hand, statistics largely unchanged in recent decades, that 
researchers have sought to develop new treatments for GBM.  The current standard of care 
involves surgical resection of the tumor, followed by radiation and chemotherapy with 
temozolomide (4). There has been some progress in the development of novel therapeutic 
strategies in GBM, including local delivery of chemotherapeutic agents using polymer 
systems, but the effects have been very modest (6, 7). Substantial efforts have also been put 
into developing targeted therapies for GBM, by attempting to take advantage of ligand 
receptors, such as those for epidermal and platelet-derived growth factors (EGF and PDGF, 
respectively), that are often over-expressed in GBM (4). 
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Recent research has also attempted to identify new avenues of therapeutic 
development by better defining the truly heterogeneous group of tumors that are classified as 
glioblastoma. Common genetic alterations include the aforementioned amplifications in EGF 
and PDGF expression, loss of heterozygosity in the chromosome q10 region, and mutations 
in the p53, PTEN, and p16 tumor-suppressor genes (8).  The clinical relevance of 
subdividing what was once thought of as a single disease is described in a recent landmark 
paper by Veerhak et al, who utilized the Cancer Genome Atlas to identify four subtypes of 
GBM: classical, mesenchymal, proneural, and neural subtypes. Their study showed that 
current treatment modalities were preferentially beneficial in classical and mesenchymal 
subtypes, while patients with the proneural subtype tended to survive longer (9). The essence 
of their work and others is that it is futile to think of GBM as a single disease entity, rather a 
group of phenotypically similar but genetically distinct tumors, and that therapies must be 
developed with this diversity in mind if they are to be beneficial to patients. 
Glioblastoma stem cells 
 Expanding upon the theme of the heterogeneity of GBM, in developing new 
therapies, it is important to attend to differences in gene expression and cellular behavior 
between tumors, as well as to those within a given tumor. It is clear at the most superficial 
level that GBM can scarcely be called a uniform mass. Its classical appearance on MRI is 
that of a ‘ring-enhancing’ lesion: an infiltrative tumor edge surrounding a necrotic core (10). 
It is also fundamentally clear that not all cells within a GBM are phenotypically the same, or 
at the very least are capable of changing under selective pressures, as evidenced by the 
recurrence of tumor following chemotherapy and radiation. It is this recurrence following 
therapy that necessitates therapeutic targeting of different cell populations within a given 
GBM.  
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In particular there is a subpopulation of tumor cells that exhibit stem cell-like 
properties. Initially described in glioblastoma in 2003 by Singh et al, these cells exhibit the 
capacity for self-renewal, differentiation, and tumor initiation (11, 12).  Such cells have been 
described in a number of different cancers, and represent a possible reservoir of malignancy 
in the tumor, capable of triggering rapid disease recurrence in the wake of therapy (13). A 
number of potential markers have been put forth as being specific for a GBM stem cell 
(GSC), most notably the membrane glycoprotein CD133, but the ultimate definition of a 
cancer stem cell is a functional one, and the use of a single marker likely excludes a number 
of cells capable of exhibiting stem cell-like behavior (11, 12).  There is significant 
controversy surrounding the definition of cancer stem cells, with delineation between the cell 
of origin for a particular tumor and all cells capable of differentiation, self-renewal, and 
tumor initiation (14). For the purposes of this discussion, the latter definition is of more 
interest, since it is cells exhibiting this pattern of behavior that are likely responsible for 
treatment failures. 
GSCs and their counterparts in other forms of cancer present unique therapeutic 
challenges. Their capacity for tumor initiation implies that should even a single cell escape 
treatment, recurrence is all but assured. Cancer stem cells asymmetrically divide, giving rise 
to a renewed stem cell and a transient amplifying cell that rapidly divides and gives rise to 
the bulk of tumor growth (15). This transient amplifying cell is readily targeted by traditional 
treatment modalities that rely on crippling cell division, such as radiation therapy or 
alkylating chemotherapeutics. However, the cancer stem cell population itself remains 
largely quiescent, thus limiting its sensitivity to these types of therapy (16, 17). Additionally, 
in some cancers, the stem cell population shows increased activity of ATP-binding cassette 
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(ABC) transporter proteins, a transport mechanism that actively extrudes chemotherapeutic 
agents from the cells (18). There is also evidence in that glioblastoma stem cells are 
inherently resistant to temozolomide therapy (19). Increased DNA damage repair and Wnt 
signaling pathway activity have also been demonstrated in multiple cancer stem cell 
populations, and also present a likely mechanism for chemoresistance (18). Further 
compounding matters in the realm of GBM is the presence of a highly necrotic and hypoxic 
tissue environment, which not only promotes the cancer stem cell phenotype, but also 
impedes delivery of any therapeutic agents to the tumor cells (18, 20). 
These unique characteristics of GSCs necessitate novel therapeutic strategies in order 
to effectively combat tumor recurrence. Attempts to treat GSCs can be broadly characterized 
into two groups. The most straightforward strategy is to find treatments to which GSCs are 
uniquely susceptible, a drug particularly toxic to GSCs or an oncolytic virus capable of 
binding to specific GSC surface ligands, for example. A second strategy is to explore agents 
that may sensitize GSCs to existing therapeutic interventions. Such an approach is attractive 
for several reasons. Firstly, the bulk tumor must still be treated in addition to the GSC 
population; so traditional chemotherapeutics/radiation therapy will remain a mainstay of 
treatment. Secondly, the capacity of GSCs for differentiation is well documented. These 
cells, as part of the natural history of the disease, divide into transient amplifying cells that 
are highly susceptible to existing therapies, so the biologic machinery for such a transition is 
clearly not only in place, but readily utilized by these cells. One needs only the proper tools 
to nudge the GSCs along this path. 
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RNA interference 
 The pursuit of such a therapeutic avenue necessitates the efficient and specific 
manipulation of the expression profile of GSCs in order to increase their susceptibility to 
chemotherapeutic agents. Through the use of small interfering RNAs (siRNAs), such fine 
control is achievable. siRNA takes advantage of the endogenous RNA interference 
machinery of the cell in order to specifically reduce the expression of a target gene at the 
messenger RNA level. 
 RNA interference (RNAi) was originally described by Fire et al in C. elegans, in 
which the authors discovered that the administration of double-stranded RNA (dsRNA) 
resulted in reduction in the levels of the mRNA of their gene of interest (21). An enzyme 
complex in the cell, termed Dicer, recognizes the dsRNA and cleaves mRNA corresponding 
to the antisense strand of the dsRNA through the formation of RNA-induced silencing 
complexes (RISCs) (22). RISCs also play a role in direct inhibition of translation and 
chromatin modification, further augmenting their gene-silencing role (22). 
 This advance in the basic understanding of cell biology led logically to the 
development of RNAi as a tool for manipulating gene expression. Administration of as 
specific dsRNA could allow for specific knockdown of a target mRNA, and allow for study 
of the effects of selective knockdown of a given gene. siRNA was developed following the 
discovery that dsRNA oligonucleotides of no longer than 21-22 base pairs were needed in 
order to achieve effective and specific knockdown of target mRNAs (23). This not only 
allowed for more efficient and economical synthesis, but also more effective transfection of 
cells and a reduction in the cellular interferon response that often accompanied 
administration of longer dsRNA molecules (this is likely because siRNA loads directly into 
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RISCs, and does not load into the Dicer complex, as do longer dsRNAs) (23). As a potential 
therapeutic platform, siRNA is extremely attractive in that it allows for exquisitely specific 
control of gene expression.  However, this specificity is also a limitation in that therapeutic 
administration of siRNA would likely only allow for the selective knockdown of a single 
candidate genes (possibly more if multiple siRNAs are co-administered, but such in such as 
scenario it is challenging to ensure equal delivery of siRNAs to the target cells). The 
likelihood of single gene therapy as a stand-alone therapeutic in GBM treatment is extremely 
unlikely. As mentioned earlier, however, the potential to sensitize GSCs to existing 
therapeutics is a promising avenue of inquiry, and one for which siRNA is ideally suited. 
Specific Aims 
Specific Aim I: Identify genes responsible for proliferation and self-renewal in glioblastoma 
stem cells that are sensitive to siRNA knockdown. 
 Given the above discussion, there is an obvious alignment between the goal of 
developing specific therapies for GSCs and the technology of siRNA-mediated RNAi. If it is 
possible to identify those genes critical for the function of GSCs, either those important for 
maintenance of their self-renewal properties or for continued proliferation and viability, then 
novel therapeutic targets will present themselves. To this end we performed a genome-wide 
siRNA library screen in order to identify candidate siRNAs. Criteria for evaluation included 
reduction in cell number, reduction in nestin expression, and changes in cell morphology. 
The former was chosen as a marker of cell proliferation and viability, while the latter two 
were selected as indicators of differentiation. 
Specific Aim II: Determine the effect of combination therapy with siRNA and 
chemotherapeutic agents on the viability of GSCs. 
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 As previously discussed, one of the most promising avenues for developing siRNA as 
a therapeutic tool in GBM is through its potential to sensitize GSCs to conventional 
chemotherapeutic agents. The likelihood of a stand-alone siRNA therapy making a 
meaningful impact in the treatment of GBM is low given the intricacy of the genetic 
derangements in the disease. However, there is an extensive literature regarding adult and 
embryonic stem cells regarding genes critical for maintenance of the stem cell phenotype 
(24-26). In addition to genes critical for maintenance of stem cell functionality, there may be 
additional genes that, when disrupted, impair GSC homeostasis sufficient to impede the 
normal mechanisms of chemotherapeutic resistance. To examine this possibility we studied 
the effect of pretreatment of a number of GSC cell lines with candidate siRNAs, followed by 
treatment with a number of chemotherapeutic agents including temozolomide, the standard 
agent in GBM therapy. 
Materials and Methods 
GSC spheroid culture 
Glioblastoma stem cell enriched spheroids were isolated from primary tumor samples 
via dissociation and culture in serum-free media as described by Lee et al (27). Briefly, cells 
were cultured as spheroids in suspension using. Neurobasal-A media (Invitrogen) 
supplemented with B27 nutritional supplement (Gibco), basic fibroblast growth factor 
(bFGF), and epidermal growth factor. (EGF). Cell culture work performed by B Himes, J 
Zhou, and T Patel. 
High-throughput screening 
Transfections using a library of ~20,000 siRNAs (Dharmacon siGENOME library, 
sequences available in Supplementary Table 2) were performed in triplicate on the GS5 GSC 
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cell line at the Yale High Throughput Screening center, using pooled siRNAs targeting 
specific genes (4 per gene) and Lipofectamine RNAiMAX transfection system (Invitrogen). 
Lipofectamine RNAiMAX reagent was diluted in OPTI-MEM serum-free media (Gibco) and 
added to 384-well plates containing pooled siRNAs. After a twenty-minute incubation, GS5 
cells were added to the transfection plates following mechanical spheroid dissociation.   
Three days following transfection, cells were formalin fixed and stained. Genes for 
secondary screening were selected based upon changes in morphology (expressed as 
increased cell length as determined by measurement algorithm developed by M Wyler), 
nestin (a stem cell marker) expression, or cell number (assessed via Hoechst 3342 nuclear 
staining). Secondary screening was performed in duplicate using 4 individual siRNAs 
targeted toward 100 genes selected based upon these three criteria.  Transfections performed 
by B Himes, T Patel, and J Zhou. Plate reading and staining performed by M Wyler. 
Statistical analysis performed by M Guie. Gene selection for secondary screen was 
performed by B Himes and J Zhou. 
Cell viability assessment 
 AlamarBlue colorimetric assays were performed 4 days following siRNA transfection 
using Lipofectamine RNAiMAX (96-well plate, 5000 cells/well). Cells were transfected at 
siRNA concentrations of 80nM and Lipofectamine concentrations of 0.3µL/well. Cells were 
incubated for 24hrs with AlamarBlue reagent (Invitrogen) prior to fluorescence reading with 
Molecular Devices Spectramax spectrophotometer. All assays performed by B Himes. 
Chemotherapeutic Combination Studies 
 Transfection conditions were the same as those described above.  Temozolomide 
(Sigma), paclitaxel (ARC), or doxorubicin (MP biomedical) was administered 24 hrs post-
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transfection diluted in DMSO (DMSO concentration 0.5% of total media volume). 
AlamarBlue reagent was added 3 days post drug treatment. Cells were incubated for 24 hrs 
with AlamarBlue reagent prior to fluorescence reading. Vehicle treatments consisted of 
DMSO only to a concentration of 0.5% of total media volume. Studies performed by B 
Himes. 
Real-Time PCR 
 Knockdown confirmation studies were performed using real-time quantitative PCR. 
Two to three days following transfection with siRNA, total cellular mRNA was harvested 
using Qiagen RNeasy Mini Kit according to manufacturers instructions. First-strand cDNA 
synthesis was accomplished using the iScript cDNA synthesis kit (Bio-Rad). Quantification 
and quality control of both harvested RNA and cDNA were performed using NanoDrop ND-
2000 spectrophotometer (Thermo Scientific). PCR primers were designed and ordered using 
PrimeTime qPCR web-based assay design software (Integrated DNA technologies). 
Detection of amplification products was performed using iQ SYBR Green Supermix and 
collected with a MyiQ detection and amplification system (Bio-Rad). Analysis of 
amplification was performed using the ΔΔCt method to calculate fold-change between 
experimental and control siRNA treated groups following data normalization to amplification 
of GAPDH control. Primer sequences available in Supplementary Table 3. All studies 
performed by B Himes.  
Immunofluorescence 
Eight-well chamber slides (Lab-Tek) were coated for a minimum of 3 hours with 
poly-L-ornithine (PLO) to induce cell adherence. Cells were plated at time of transfection 
with Lipofectamine RNAiMAX (Invitrogen) at a density of 10,000 cells/well. Fixation and 
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staining were performed three days post-transfection. GFAP staining was performed using 
rabbit polyclonal antibody (Dako) and goat anti-rabbit AlexaFluor 546 secondary antibody 
(Invitrogen). Images were acquired using an Olympus IX71 microscope. Image analysis and 
quantification performed using ImageJ software. Briefly, images were imported in .tif format 
and normalized by setting a baseline signal threshold to remove background signal. ImageJ 
software then was used to calculate the integrated density of the image (sum total of all 
normalized pixel intensities). This data was then divided by the number of cells per image to 
account for changes in cell number across fields of view.  
Results 
Genome-wide screening 
 In order to identify genes important for GSC maintenance and viability that are 
potentially susceptible to siRNA-mediated therapy, we performed a genome-wide screen 
using the Dharmacon siGenome library. This library consists of approximately 18,000 
siRNAs spread over fifty-eight 384-well plates, with 4 siRNAs specific to each gene. The 
primary screen was performed in triplicate using the GS5 GSC line. Cells were transfected 
with siRNA from the library and plated on PLO-coated 384-well plates. Three days post-
transfection, cells were formalin fixed and stained in order to quantify changes in cell 
number, changes in nestin expression, and changes in cell morphology. Results were sorted 
based on degree of reduction in cell number relative to control wells, statistically significant 
reduction in nesting expression according to a robust z-score (RZ), and a significant increase 
in the percentage of lengthy cells, also determined by a robust Z score. The data were highly 
reproducible across each of the three replicates (see Figure 1). Control siRNAs included a 
nestin siRNA as a positive control and a RISC-free siRNA as a negative control (a 
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proprietary siRNA that is not processed by the RISC complex, minimizing the off-target 
effects seen with scramble siRNAs (28)). 
 
Figure 1. High-throughput siRNA screening is reproducible. Plots of signal intensity 
from each of three replicate siRNA plates plotted against one another. Note the strong 
correlation across plates. 
 From this initial dataset, genes were selected for confirmation screening, wherein 
transfections were repeated using a single siRNA per well rather than pooled siRNAs 
targeting a specific gene. Transfection and staining was performed in an identical manner to 
the primary screen, again in triplicate using the GS5 cell line, with four siRNAs for each 
gene. Genes selected for confirmation screening were chosen due to a substantial decrease in 
cell number (greater than 50% reduction in cell number in at least 2/3 replicates), a low cell 
width: length ratio significantly different than that of the negative control cells (RZ>7), or a 
significant reduction in nestin expression (RZ<-2). Due to limitations with the scope of the 
pilot study through the Yale High-Throughput Center, only one hundred genes could be 
selected for confirmation screening, and as such significant weight was given to the likely 
biologic activity of the candidate siRNAs, and an extensive search of the literature was 
undertaken to investigate the applicability of the candidate genes in GBM pathogenesis, GSC 
maintenance, or in other cancer or stem cell biology. The full list candidate genes selected 
can be found at the end of this manuscript (supplementary table 1). 
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 Genes evaluated on cell length criteria were termed a confirmed hit if one siRNA in 
each of the three replicates produced a decrease in cell width: length ratio with a RZ score of 
greater than 2. Genes evaluated on cell viability metrics were deemed hits if a siRNA 
resulted in at least a 30% decrease in cell number across all replicates. Those genes evaluated 
on the criteria of nestin expression were confirmed as hits if one siRNA in each of the three 
replicates reduced nestin expression relative to control by at least 30%. Of the one hundred 
genes screened, there were seven confirmed hits based on reduction in nestin expression, six 
were confirmed based on reduction in cell viability, and fifteen were confirmed based on 
increased cell length criteria (Tables 1, 2, and 3). 
Cell Viability 
Confirmed Hits    
Name Aliases Description 
Entrez 
Gene ID References 










RPS6 RP11-513M16.6, S6 
ribosomal protein 
S6 6194 Mayer (31) 
SIK2 LOH11CR1I, QIK, SNF1LK2 
salt-inducible kinase 
2 23235 Bright (32) 
UBC HMG20 ubiquitin C 7316 Chen (33) 
WEE1 FLJ16446; DKFZp686I18166 Ser/Thr kinase  7465 Mir (34) 
 
Table 1. Confirmed cell viability hits. Genes with a reduction in cell viability of at least 
30% in at least one instance across all three replicates. Aliases and descriptions taken from 
Entrez Gene available at http://www.ncbi.nlm.nih.gov/gene/. 
Nestin Reduction Confirmed Hits    
Name Aliases Description 
Entrez 
Gene ID References 
AKT1 AKT, PKB, PKB-ALPHA, PRKBA, RAC, 
v-akt murine thymoma 
viral oncogene homolog 1 207 Eyler (35)  
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RAC-ALPHA 
DUB3 DUB3; USP17L2 
ubiquitin specific 
peptidase 17-like 2 377630 Pereg (36)  
H-PLK HPF9; H-plk; MGC22613; ZNF117 zinc finger protein 117 51351  
HSPA6  
heat shock 70kDa protein 
6 (HSP70B') 3310 
Gama Fisher 
(37)  
MRLC2 MLC-B; MRLC2; MYL12B 
myosin, light chain 12B, 
regulatory 103910  
TKTL1 TKR; TKT2; TKTL1 transketolase-like 1 8277 Yuan (38) 
 
Table 2. Confirmed nestin reduction hits. Genes with a reduction in nestin expression of at 
least 30% in at least one instance across all three replicates. As above, aliases and 
descriptions taken from Entrez Gene. 
Cell Length Confirmed Hits   
Name Aliases Description 
Entrez 






Apoptosis-related protein 3- 
multiple splice sites 51374 Yu et al (39) 
COMMD1 MURR1; C2orf5; MGC27155; 
copper metabolism (Murr1) 
domain containing 1 150684 
Zoubeidi 
(40)  














receptor 2 9294 Estrada (43) 
ETS2 
ETS2IT1 
v-ets erythroblastosis virus 
E26 oncogene homolog 2 
(avian) 2114 Valter (44) 
MAP3K2 MEKK2, MEKK2B 
mitogen-activated protein 
kinase kinase kinase 2 10746 Xia (45)  
MRLC2 MLC-B; MYL12B 
myosin, light chain 12B, 




Brn3a, POU class 4 homeobox 1 5457  
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E130119J07Rik 
RARG RARC; NR1B3 
retinoic acid receptor, 





ras homolog gene family, 
member A 387 
Hoshino 
(47) 
TEF KIAA1655; TEF 
thyrotrophic embryonic 





von Willebrand factor C 





WAP four-disulfide core 
domain 11 259239  
ZNF513 RP58; FLJ32203; HMFT0656 zinc finger protein 513 130557  
 
Table 3. Confirmed cell length hits. Genes with corresponding siRNAs inducing a 
significant increase in cell length with a RZ score greater than 2 for at least one siRNA in all 
replicates. As above, alias and description information taken from Entrez Gene database. 
 As noted in the above tables, a number of these confirmed target genes have known 
roles in glioblastoma pathogenesis or are prominently involved in other cancers. Some of the 
confirmed genes, such as DVL2, have even been shown to be important in the maintenance 
of GSCs (30). This documented biologic relevance provides encouragement that some of the 
identified genes may have therapeutic applications, and the nature of the screen is indicative 
of their relative susceptibility to treatment with siRNA. 
 However, there are limitations to this screening approach and the data generated from 
this study. Notably, the primary screen and subsequent confirmation studies were only 
performed on the GS5 cell line. Given that siRNA therapy only targets a single gene at a 
time, it is essential to confirm the efficacy of knocking down the expression of a given target 
gene in multiple genetically diverse GSC populations. While there is undoubtedly tumor 
heterogeneity that needs to be taken into account as targeted therapies such as siRNA 
	  	   	   	  
15	  
platforms are developed, it is also critical to develop therapies that have as broad 
applicability as feasible. There is also some concern with the use of nestin as a marker for 
GSC maintenance and its absence as a marker for differentiation. While there is a wide 
literature on the use of nestin as a stem cell marker, the short timescale of this screen coupled 
with the often subtle changes observed in nestin intensity may call its utility here into 
question. Finally, many of the effects observed overall in the screen were relatively small, 
albeit reproducible. This is not surprising when one considers that siRNA treatment reduces 
the expression of a single target gene, and in a population of cells that are typically quiescent, 
there is likely a robust ability to overcome such modest derangements. Yet, the fact that these 
effects are reproducible and statistically significant points to a real and measurable change in 
cell behavior. If the siRNA itself does not provide a stand-alone therapeutic option, then 
perhaps it can be used to enhance the utility of other therapeutic agents that have hitherto 
been ineffective in treating GSCs. 
Treatment across cell lines 
 Moving forward in our studies, we focused our efforts on a more narrow group of 
genes than those confirmed by the initial screen. We determined that those genes that have a 
direct effect on GSC viability were the best candidate targets moving forward, as knockdown 
of these genes produced the most dramatic effect of the three criteria measured (cell death), 
and also the most easily quantifiable one. Five genes were selected for further study: UBC, 
DVL2, CCNB1, WEE1, and TPX2. The latter gene, an Aurora kinase-associated protein, did 
not meet the criteria used to define a hit on the cell viability confirmation screen because it 
did not induce sufficient cell death in one of the three replicates. However, because of its 
implications in a number of oncogenic pathways, and because in the other replicate plates, 
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three and two of the four siRNAs targeting TPX2 resulted in cell death meeting the criteria 
for a hit, we decided it merited further study (48). 
 To examine the effects of siRNA knockdown of these candidate genes on multiple 
cell lines, cells from the GS5, PS11, PS16, and PS32 lines were treated with siRNAs 
targeting TPX2 and UBC. Previous work in the laboratory to categorize these cell lines has 
shown that they express dramatically different levels of key genes in glioblastoma 
pathogenesis, such as NF1, EGFR, and PDGFRA (Michael Fu, unpublished data, see 
Supplementary Figure 1.). AlamarBlue assays performed following transfection with siRNA 
demonstrated a significant reduction in cell viability with siUBC treatment across all cell 
lines (Figure 2). A reduction in cell viability across all lines was also observed with siTPX2 
treatment, but it did not reach statistical significance. 
 
Figure 2. UBC knockdown reduces cell viability across multiple cell lines. AlamarBlue 
data (assay on d4 post-transfection, n=3 biological replicates with three technical replicates 
each) demonstrates a significant reduction in cell-viability relative to RISC-free siRNA-
treated control. * = p<0.05 by t-test. Error bars = SEM. 
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Figure 3. Knockdown of siCCNB1, DVL2, and WEE1 produces a significant reduction 
in cell viability across cell lines. AlamarBlue data (assay on d4 post-transfection, n=3 
biological replicates with three technical replicates each) demonstrates a significant reduction 
in cell-viability relative to RISC-free siRNA-treated control. * = p<0.05 by t-test. Error bars 
= SEM. 
Similar studies were performed using siCCNB1, siDVL2, and siWEE1. These studies 
were only carried out on the GS5 and PS16 cell lines however, due to the higher reliability of 
the lipid-based transfections in these cell lines. In these studies, all siRNAs showed a 
significant reduction in cell viability relative to treatment with control siRNA in both cell 
lines. This effect was not as substantial as that observed in with siUBC, however (Figure 3). 
   In order to confirm that the siRNAs under study actually reduce expression of the 
target genes in question, the levels of target gene mRNA following siRNA transfection were 
assessed. To this end we performed real-time quantitative PCR to assess target gene mRNA 
levels 48 hours following transfection (Figure 4).  These studies demonstrated substantial 
knockdown of expression of all candidate genes, most notably UBC. Knockdown of WEE1 
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and CCNB1 were less than ideal, with less than 50% knockdown in expression, though given 
the observed efficacy in cell viability reduction this seems more likely due to suboptimal 
transfection efficiency. Overall however, these results support that the observed reduction in 




Figure 4. Confirmation of target gene mRNA knockdown. Quantitative real-time PCR 
results for mRNA expression of target genes after treatment with a given siRNA relative to 
RISC-free siRNA-treated controls. Data is an average of three technical replicates each of 
GS5 and PS16 cell lines. Error bars = SEM. 
Chemotherapeutic studies 
 The data demonstrate a consistent effect of siRNA treatment across multiple cell lines 
in reducing cell viability (Figures 2 through 4). However, this effect, with few exceptions 
(such as siUBC treatment of the PS11 cell line) was modest. This is not surprising. While 
there are some tumors in which a given genetic target is critical for cancer cell maintenance, 



















mRNA knockdown confirmation 
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typically heterogeneous (49, 50). It is highly unlikely, given the variety of genetic 
derangements in GBM and the relative quiescence of the GSC population that modulation in 
expression of a single gene would be able to eliminate this problematic group of cells across 
a number of different cell lines. 
 However, the observed effects indicate a reproducible, albeit modest, response to 
siRNA therapy in these cells. If the siRNA therapy alone is insufficient to kill this cell 
population, we reasoned that it may be sufficient to sensitize GSCs to traditional 
chemotherapeutic agents either by induction of differentiation or through disruption of 
cellular homeostasis. As mentioned earlier, GSCs are typically resistant to temozolomide, the 
current chemotherapeutic standard of care in GBM (19, 51). The ability of a single factor to 
induce differentiation of adult or embryonic stem cells, differentiated cells, or cancer stem 
cells is well documented (52-54). 
 To determine the impact of siRNA therapy on GSC response to chemotherapeutic 
agents, we transected cells with candidate siRNAs, and then treated cells with temozolomide 
at a concentration of 500µM for 24hr after transfection (this large concentration of 
temozolomide was used in order to attain a reliable 50% reduction in cell viability by 
AlamarBlue assay). Cell viability was assessed by colorimetric assay three days following 
drug treatment. Studies were conducted using the GS5 and PS16 cell lines. 
 A dramatic decrease in cell viability was observed in the siUBC-treated following 
addition of temozolomide (TMZ) treatment, with reductions in florescence of over 80% 
relative to vehicle and RISC-free treated control (Figure 5, top and bottom). This observation 
reached statistical significance relative to treatment with temozolomide and RISC-free 
siRNA in both cell lines tested. A similar additive effect was seen across all siRNA+TMZ 
	  	   	   	  
20	  
combinations, but the only other to reach statistical significance was siDVL2+TMZ in the 
PS16 cell line. A notable decrease in cell viability was also observed in the siTPX2+TMZ 
and siDVL2+TMZ treated GS5 cells, and in the siCCNB1+TMZ treated PS16 cells, but these 
changes did not reach statistical significance when compared to siRISC-free+TMZ treated 
cells (in all cases p~0.1). 
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Figure 5. siRNA treatment augments the effect of temozolomide (TMZ) on GSCs. 
AlamarBlue assays following treatment with siRNA and subsequent temozolomide treatment 
at 500µM in the PS16 (top) and GS5 (bottom) cell lines. * = p<0.05 ** = p<0.01. Error bars 
= SEM. 
 The above studies demonstrate that when used in combination with temozolomide, 
siRNA therapy directed toward a number of our selected candidate genes, particularly UBC, 
can have a dramatically larger effect on GSC viability than siRNA or chemotherapy alone. 
This is in line with the hypothesis that siRNA can be used to sensitize GSCs to 
chemotherapeutic agents. It is important to note that the concentrations of temozolomide 
used in these experiments are substantially higher than those used in clinical practice; this 
was done in order to achieve a reliable dose response. 
GSC differentiation 
 In the primary siRNA library screen described earlier, genes were selected based on 
markers of differentiation (nestin expression and increased cell length) in addition to 
reduction in cell number. The latter category was chosen out of an interest in determining 
those genes most directly responsible for GSC maintenance and critical for their survival, as 
well as due to its ease of quantitation. However, in exploring the reasons behind the above 
described effect of increased sensitivity to temozolomide, it is important to consider the 
possibility that these genes important for viability may also be important for maintaining the 
stem cell properties of GSCSs, or that the reduction in their expression causes sufficient 
derangement in GSC homeostasis so as to force differentiation.  In order to assess this 
possibility, we performed immunofluorescent staining of GS5 cells following transfection 
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with the previously examined genes identified based on impact on cell viability. Three days 
after transfection, cells were fixed and stained for glial fibrillary acidic protein (GFAP), a 
marker of astrocytic differentiation (Figure 6) (55, 56). GSCs typically express some level of 
GFAP, but GSCs often express less than bulk tumor or normal glial cells (27, 57). Increased 
staining for GFAP was observed in most treatment conditions, particularly in those cells 
transfected with siDVL2 and siCCNB1. A more modest increase in GFAP staining was 
observed in those treated with siUBC, siTPX2, and siWEE1. 
 In an effort to quantify the expression of GFAP in these studies, we utilized the 
ImageJ software package to analyze levels of fluorescence. As most cells in all studies 
stained at least weakly for GFAP (very weakly in the case of the RISC-free treated cells 
which was expected based on the literature (11)), we chose to quantify the overall GFAP-
coupled fluorescence as it related to the number of cells in a given field of view (Figure 6, 
bottom). By setting a threshold level of fluorescent detection, we controlled for background 
fluorescence and used to software to measure the total signal intensity of GFAP-couple 
fluorescence in a particular field of view. To control for variations in cell number, this total 
fluorescence was divided by the number of cells the field. 
 The data generated by this method largely corroborate the above observations based 
on gross visual inspection. All therapeutic conditions showed a higher level of GFAP 
fluorescence than the siRISC-free treated GSCs.  DVL2 in particular showed a high level of 
fluorescence with relatively little variability across fields of view. Expression in other 
experimental conditions, notably that of the siWEE1-treated cells, was much more variable, 
though clearly greater than control levels. 




Figure 6. Changes in GFAP staining of PS16 GSCs following siRNA transfection.  Top: 
Immunofluorescent staining for GFAP (AlexaFluor 546, green) or DAPI nuclear stain (blue). 
Bottom: Quantification of GFAP fluorescence following siRNA transfection and staining 
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 These results indicate some level of increased glial differentiation in GSCs treated 
with these siRNAs, pointing to a potential mechanism for the observed increase in sensitivity 
to temozolomide treatment. Direct toxicity to GSCs is likely of equal if not greater 
importance than induced differentiation in the case of several of these siRNAs, however, as 
transfection with siUBC, which resulted in the greatest decrease in cell viability, caused only 
a small increase in GFAP staining. Transfection with siDVL2, however, resulted in both a 
substantial decrease in cell viability and the most dramatic increase in GFAP expression 
observed, indicating a possible link between the two in this instance. 
Discussion 
 In an effort to identify novel therapeutic targets for glioblastoma, we performed a 
genome-wide screen using a library of candidate siRNAs, examining their effects on 
glioblastoma stem cells. We identified a number of genes important for GSC proliferation 
and maintenance by measuring changes in cell number, nestin expression, and cell 
morphology. We demonstrated the efficacy of candidate genes identified in this screen in 
reducing GSC viability in several genetically distinct GSC cell lines. Further, we showed that 
several of these candidate siRNAs, most notably siUBC, significantly and substantially 
increase the sensitivity of GSCs to treatment with temozolomide, raising the possibility of a 
role for siRNA as an adjunct therapeutic for treating GBM. Finally, we explored the 
mechanism of this increased sensitivity, demonstrating that in addition to the impediment to 
cell proliferation observed on the initial screen, transfection with number of the candidate 
siRNAs leads to GSC differentiation as measured by increased GFAP expression. These data 
all support the potential use of siRNA, particularly siUBC as identified in these studies, as a 
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worthwhile therapeutic avenue to pursue in the treatment of the therapeutically challenging 
GSC population.   
Biologic relevance 
 In any study involving a genome-wide screening approach, it is important to proceed 
with an eye to the biologic functionality of the candidate genes evaluated in order to make 
sense of what can be a daunting amount of data. As demonstrated in Table 1, 2, and 3, a 
number of the genes identified in both the primary and confirmation screens have direct 
biologic relevance to cancer or stem cell biology in general, or to glioblastoma in particular. 
  The ubiquitin gene encodes a protein critical for the maintenance of protein 
homeostasis in cells, targeting proteins for degradation by the proteosome complex (58). 
Given the role of the protein in such fundamental process, ubiquitin is a key component of 
many cellular processes, including cell cycle, where it triggers the degradation of a number 
of cyclin checkpoint proteins, as well as their inhibitors (33, 59). This implies an important 
role of the proteosome and its regulatory pathways in the cell cycle regulation of both normal 
and malignant cells, making it a potentially attractive therapeutic target. Proteosome activity 
is increased in a number of cancers, including breast cancer and melanoma, and increased 
proteosomal activity is thought to allow cellular avoidance of apoptosis (33, 60-62). In fact, 
inhibition of the proteosome and has been shown not only to increase apoptosis, but 
bortezomib, a proteosome inhibitor, has even been shown to aid in overcoming 
chemoresistance (33). 
 DVL2, part of the Wnt signaling pathway, has recently been described as playing a 
significant role in glioblastoma in a manner consistent with that observed in our studies (30). 
Pulvirenti and colleagues, using bulk tumor glioblastoma lines, as well as primary GBM 
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samples, demonstrate that DVL2 is frequently highly expressed in these tumors, and that 
inhibition of DVL2 expression through siRNA knockdown inhibits cell proliferation.  They 
also show that DVL2 knockdown inhibits tumor formation in a mouse model, and, 
interestingly, lead to increased differentiation of tumor cells (30). Derangements in Wnt 
pathway expression, including DVL2, while not extensively described in glioblastoma, are a 
common area of study in other cancers, including colorectal and non-small cell lung cancer 
(63, 64). 
 Despite a less dramatic observed effect on GSCs in our studies, TPX2 also remains an 
interesting candidate gene. A microtubule-associated gene, TPX2 has garnered some interest 
as a potential therapeutic target as it regulates the protein Aurora, which is critical for 
chromosomal segregation in mitosis (65). Very recently, however, Guvenc and colleagues 
described inhibition of the Survivin-Ran protein complex, for which TPX2 is an effector 
protein, as importance for GSCs survival (66). They describe inhibition of GSC spheroid 
growth as well as cell death through a caspase-mediated mechanism. Though they did not 
investigate TPX2 itself as a therapeutic target in this study, they demonstrate a key pathway 
of which it is a part to be an intriguing therapeutic option, specifically in treating GSCs. 
 Similar biologic evidence can be found for many of the other candidate genes 
identified as listed in the earlier tables and in the supplementary table below. CCBN1 is a 
protein critical for cell cycle that has long been the subject of investigation in oncology (67). 
Similarly, WEE1 has been the focus of study given its role in cell cycle progression (68). In 
this way we feel that the siRNA screening approach accomplished our goal to identify novel 
GSC therapeutic targets that are biologically relevant and have the potential to be 
therapeutically meaningful.  
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Future directions 
 Given the large number of candidate genes identified through the genome-wide 
screen, a great deal of study remains to be done in assessing the importance of the genes 
identified. Given the possible role of differentiation in sensitizing GSCs to chemotherapy, 
even in those cells identified because of their toxicity to GSCs, it is essential to revisit those 
genes identified based on changes in nestin expression and increased cell length in order to 
examine the effects of chemotherapy following treatment with these siRNAs. However, those 
genes identified based on toxicity discussed above, if they truly induce differentiation in 
addition to being toxic to GSCs, will likely prove the best therapeutic candidates. 
 We have begun exploring the potential for siRNA combination therapy by performing 
simultaneous transfection with multiple candidate siRNAs. A central problem with siRNA 
treatment in cancer therapy is the idea that siRNA can only reduce the expression of a single 
specific gene. While it is this exquisite specificity that makes siRNA such an attractive 
research tool, it is a limitation in treating a disease as genetically complex as GBM. By 
combining siRNAs that act on genes in different critical pathways, we hope to explore the 
potential for siRNA as a stand-alone therapy if the correct cocktail of siRNAs is utilized. We 
have begun some preliminary studies to examine the effects of using those siRNAs identified 
as reducing cell viability in combination with one another, and have also begun to examine 
the use of siRNAs identified based on induction of differentiation in combination with the 
most toxic siRNA identified, siUBC (See Supplementary Figures 2 and 3). 
 Studies are also underway to examine the effects of different chemotherapeutic agents 
in conjunction with siRNA therapy. While temozolomide represents the standard of care in 
GBM, siRNAs that are ineffective in sensitizing GSCs to temozolomide therapy might be 
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more effective if a different agent, such as paclitaxel or doxorubicin, is used. We have begun 
to examine the effects of paclitaxel and doxorubicin treatment in GSCs in conjunction with 
our siRNA therapy, and early results show similar effects to that observed with 
temozolomide (Figure 7.) 
 
Figure 7. Paclitaxel and doxorubin in combination with siRNA therapy in GS5 cells.  
AlamarBlue assays demonstrate reduced cell viability with siRNA therapy followed by 
treatment with either 250nM paclitaxel of 24nM doxorubicin. Interpretation of this data is 
challenging as these drugs are much more toxic to GSCs than temozolomide, making it 
difficult to assess any additional impact of siRNA treatment. n = 3 for RISC-free, UBC, and 
TPX2; n = 2 for DVL2. Error bars = standard error. 
 Ultimately, however, the utility of siRNA therapy, both alone and in conjunction with 
chemotherapy, must be demonstrated in an in vivo model in order to better assess the 
therapeutic viability of these candidate genes. GSCs form tumors in a xenograft model; the 
challenge lies in effective delivery of siRNA to the tumor, where endogenous nucleases, 
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Clinical applicability  
A number of proposed solutions have arisen in order to combat the problem of siRNA 
delivery, which must be overcome to translate therapeutics to clinical practice.  Modification 
of the RNA molecule itself in order to make it more resistant to nuclease degradation is one 
widely used method.  2’-O-methylation of the sugar backbone at several nucleotides within 
the siRNA molecule allow for not only increased resistance to RNAse activity, but also 
reduced inflammatory response and some limitation of off-target effects (70).  Liposomal 
delivery systems have also shown some promise in delivering siRNA to target tissues intact 
(71). Additionally conjugation to antibodies and other protein moieties has shown some 
potential for improved targeted delivery (71, 72).  All of these technologies, however, have 
failings in one or more areas that impede their ability to become an effective solution for the 
problem of therapeutic siRNA delivery.  Structural reinforcement of the siRNA may improve 
resistance to degradation, but it does little to effectively target siRNA delivery or assure 
entrance into the cell cytoplasm.  Antibody conjugation allows for targeted delivery, but is 
limited in the degree to which it can be modified for effective diffusion through tissues and 
are limited to recognizing a single receptor group.  Liposomal constructs may have 
limitations to the extent to which they can achieve specific delivery, and do not provide a 
means of administering controlled release (73).     
Synthetic nanoparticles hold promise in solving the delivery problems surrounding 
siRNA delivery.  Nanoparticles are constructed with biodegradable and biocompatible 
materials, can be coated with materials to increase bioavailability and provide targeted 
delivery, can be fabricated in different formulations and sizes for controlled release, and can 
be loaded with agents to aid in the efficacy of siRNA: these properties have the potential to 
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solve the major delivery challenges surrounding siRNA (70). The use of biodegradable or 
biocompatible materials increases the safety profile and allows for controlled release of 
loaded material, and the ability to coat the particles with agents like polyethylene glycol 
(PEG) to increase the hydrophilic nature of the molecules improves their penetration into 
target tissues (74, 75). Recently, Woodrow et al. and Zhou et al. have demonstrated the use 
of poly(lactic-co-glycolic acid) (PLGA) nanoparticles that can be readily modified to allow 
for effective siRNA delivery (76, 77).  PLGA, known to be biodegradable, is also readily 
modified to adjust the rate of release of loaded agent (78).  These particles make use of 
conjugated peptides such as iRGD, which has been shown to enable particles to home to a 
target tumor when administered systemically (79). They may also be loaded with agents to 
enhance endosomal survival and escape, and to increase the potency of siRNA (80, 81). With 
all of these finely tunable elements, these nanoparticles hold great potential as a powerful 
delivery vehicle for siRNA-based therapy. 
In sum, with advances in delivery technology, siRNA is rapidly becoming a feasible 
means by which one can realistically hope to treat disease. The question becomes, then, of 
choosing the delivery system and candidate siRNAs most appropriate for the disease process 
in question. Much recent work in the Saltzman lab has centered on the development of an 
effective nanoparticle delivery system for siRNA, as well as studying convection-enhanced 
delivery of these nanoparticles intracranially. For these reason we embarked on this genome-
wide screen to identify potential therapeutic targets with which to take advantage of this 
platform. Now that a number of interesting candidate genes have been identified, it is time to 
marry the platform and the payload, and attempt to develop a novel therapy for glioblastoma.  
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Supplementary Table 1. Genes selected for confirmation screening. 
Name Description 
Entrez 
Gene ID References 
ACVRL1 activin A receptor 
type II-like 1 94 Dieterich (82) 




oncogene homolog 1 207 Eyler (35) 
ALDOA aldolase A, fructose-bisphosphate 226  
ARRB1 arrestin, beta 1 408 Bonnas (84) 
ARRB2 ARB2, ARR2, BARR2 409  
AURKB 
AIK2, AIM-1, AIM1, 
ARK2, AurB, IPL1, 
PPP1R48, STK12, 




complex-1, subunit 1 2647  
BMP4 bone morphogenetic protein 4 652 Piccirillo (86) 




member 4 57091 Singh (88) 
C2ORF28 
Apoptosis-related 
protein 3- multiple 
splice sites 51374 Yu (39) 
CARD9 caspase recruitment 
domain family, 
64170 Adrian (89) 
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member 9 
CASP8AP2 caspase 8 associated protein 2 9994 Lee (90) 
CCNB1 cyclin B1 891 Horvath (29) 
CCNB1IP1 
cyclin B1 interacting 
protein 1, E3 ubiquitin 
protein ligase 57820  




containing 1 150684 Zoubeidi (40) 
COMMD3 COMM domain containing 3 23412 Cai (91) 
CRYAA crystallin, alpha A 1409 Goplen (41) 
CSNK1A1 casein kinase 1, alpha 1 1452 Bak (92) 




beta 1, 88kDa 1463 Chiba (94) 
DDB1 
damage-specific DNA 
binding protein 1, 
127kDa 1642 Jiang (42) 




containing 14A 25864  
DPP4 dipeptidyl-peptidase 4 1803 Yang (96) 










(Drosophila) 1856 Pulvirenti (30) 




accessory protein 2) 2004 Wasylyk (97) 
EPAS1 endothelial PAS domain protein 1 2034 Liang (98) 
ETS2 
v-ets erythroblastosis 
virus E26 oncogene 
homolog 2 (avian) 2114 Valter (44) 




oncogene homolog B 2354 Kesari (100) 
FRAP1 
mechanistic target of 
rapamycin 
(serine/threonine 
kinase) 2475 Sunayama (101) 
GNG2 
guanine nucleotide 
binding protein (G 
protein), gamma 2 54331  
GSH-2 GS homeobox 2, role in neural development 170825 Waclaw (102) 
H-PLK zinc finger protein 117 51351  
HBM hemoglobin, mu 3042  
HIF1A 
hypoxia inducible 
factor 1, alpha subunit 
(basic helix-loop-
helix transcription 
factor) 3091 Yoshida (103) 
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HOXB3 homeobox B3 3213 Bodey (104) 
HSP90B1 
heat shock protein 
90kDa beta (Grp94), 
member 1 7184 See (105) 
HSPA5BP1 
transmembrane 
protein 132A 54972 Oh-Hashi (106) 
HSPA6 heat shock 70kDa protein 6 (HSP70B') 3310 Gama Fisher (37) 
IRAK2 interleukin-1 receptor-associated kinase 2 3656 Muzio (107) 
KIF15 kinesin family member 15 56992 Rath (108) 
KIF3A kinesin family member 3A 11127 Rath (108) 
MAP3K2 
mitogen-activated 
protein kinase kinase 
kinase 2 10746 Xia (45)  
MAP3K6 
mitogen-activated 
protein kinase kinase 
kinase 6 9064 Sirotkin (109) 
MAPK12 mitogen-activated protein kinase 12 6300  








(matrilysin, uterine) 4316 Rome (111) 
MRLC2 myosin, light chain 12B, regulatory 103910  
NOTCH3 notch 3 4854 Kanamori (112) 
NRN1 neuritin 1 51299 Le Jan (113) 
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isozyme 1 5163 Lee (115) 





like 84457  
POU4F1 POU class 4 homeobox 1 5457  
PRAF2 association with glioma 11230 Bosics (116) 
PRB1 proline-rich protein BstNI subfamily 1 5542 Collins (117) 
PRES 
prestin (motor 
protein) - possible 




alpha type, 1 5682 Wernike (118) 
RARG retinoic acid receptor, gamma 5916 See (119)  
RHOA ras homolog gene family, member A 387 Jin (47) 
RHOC ras homolog family member C 389 Sasayama (120) 
RPS27A ribosomal protein S27a 6233 Noerholm (121) 
RPS6 ribosomal protein S6 6194 Mayer (31) 
SATB1 SATB homeobox 1 6304 Chu (122) 
SERPINB2 
serpin peptidase 
inhibitor, clade B 
(ovalbumin), member 
5055 Motaln (123) 
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2 
SFRS3 serine/arginine-rich splicing factor 3 6428 Jia (124) 
SIK2 salt-inducible kinase 2 23235 Bright (32) 
SMO smoothened, frizzled family receptor 6608 Shahi (125) 
SNAI2 snail homolog 2 (Drosophila) 6591 Yang (126) 
TEF thyrotrophic embryonic factor 7008  
TF transferrin 7018 Martell (127) 
TFAP2BL1 
transcription factor 
AP-2 delta (activating 
enhancer binding 
protein 2 delta) 83741  
TGFB2 transforming growth factor, beta 2 7042 Schneider (128) 
THAP5 THAP domain containing 5 168451 Ola (129) 
TKTL1 transketolase-like 1 8277 Yuan (38) 
TNEM23 
sphingomyelin 
synthase 1, possible 
role in apoptosis 259230 Lafont (130) 




(Xenopus laevis) 22974 Asteriti (48) 
TRAF3 TNF receptor-associated factor 3 7187 Xie (132) 
TSC2 tuberous sclerosis 2 7249 Mieulet (133) 
TSC tuberous sclerosis 1 7248  
UBB ubiquitin B 7314 Chen (33) 
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UBC ubiquitin C 7316 Chen (33) 
UNQ739 
von Willebrand factor 
C domain containing 
2 375567  
WEE1 Ser/Thr protein kinase.  7465 Mir (34) 




family, member 9B 7484  
YAP Yes-associated protein 1 10413 Hélias-Rodzewicz (134) 
ZDHHC18 zinc-finger 84243  
ZNF322A zinc finger protein 322A 79692  
ZNF513 zinc finger protein 513 130557  
 
Supplementary Table 2. siRNA sequences from the Dharmacon siGENOME library. 
 







Supplementary Table 3. Real-time qPCR primers. 
 
Gene 5'->3' Sequence Tm (°C) %GC 
UBC    
Forward ACGCACCCTGTCTGACTACAACAT 60 50 
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Reverse AGGGATGCCTTCCTTGTCTTGGAT 60 50 
TPX-2    
Forward AAGAAGCCAGAGGAAGAAGGCAGT 60 50 
Reverse AGAAACTTCTGCTTTGCAGGTGGC 60 50 
RHOA    
Forward AGGTAGAGTTGGCTTTGTGGGACA 59.9 50 
Reverse TATTCCCAACCAGGATGATGGGCA 60 50 
CCNB1    
Forward TGTGGATGCAGAAGATGGAGCTGA 59.9 50 
Reverse TTGGTCTGACTGCTTGCTCTTCCT 60 50 
DVL-2    
Forward ATGTGGCTCAAGATCACCATCCCT 59.9 50 
Reverse TCTTGTTGACGGTGTGTCGGATCA 60 50 
WEE1    
Forward AAACAGCCCTTGGTTTGGCCTATG 59.8 50 
Reverse TATAACCTGGGAAGCGCTGTGGAA 59.9 50 
HSPA5BP1    
Forward ATGGTGTGGGAAATCCTGGTGTCT 60.1 50 
Reverse TGTATTCACCAGCTCCTCAGCCTT 59.8 50 
C20ORF32    
Forward ACCGCATCCTGCTTGAAACAAAGG 60.1 50 
Reverse GGCAATGACAATGGAGGCAAACCT 60 50 
GAPDH    
Forward TCGACAGTCAGCCGCATCTTCTTT 60.3 50 
Reverse ACCAAATCCGTTGACTCCGACCTT 60.1 50 
PLK    
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Forward TGTACATGTTCGGGTGTGGGTTCT 60 50 
Reverse AAGCCAAGGAAAGGACAGTTCCGA 60.3 50 
 
 
Supplementary Figure 1. Differential expression of genes across GSC lines. Real-time 
PCR data studies performed by Michael Fu demonstrate broad variability in the expression of 
key genes in GBM pathogenesis across numerous GSC cell lines. Note the positions of the 
GS5 and PS16 lines. Results shown as standard deviations from mean expression across all 
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Supplementary Figure 2. siRNA combination treatment in PS11. Simultaneous treatment 
with two different siRNAs at a concentration of 40nM as compared to 80nM single RNA 
doses. Data is preliminary and few substantial effects seen, though there is perhaps a 
marginally larger effect in the siCCNB1/siTPX2 combination than in either alone, though it 
is highly variable. Data are results of AlamarBlue assays performed in the manner described 
above. n=2 biological replicates with 3 technical replicates each. Error bars = standard error. 
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Supplementary Figure 3. Differentation-inducing siRNA combination with siUBC in 
GS5. Preliminary data demonstrating the effect of the combination of genes identified as 
inducing GSC differentiation (see Tables 2 and 3) with siUBC, the siRNA most consistently 
effective in reducing cell viability. Above data are the results of one AlamarBlue assay 
conducted in the manner described above. 1.	   Ohgaki,	  H.,	  and	  Kleihues,	  P.	  2005.	  Epidemiology	  and	  etiology	  of	  gliomas.	  Acta	  
Neuropathol	  109:93-­‐108.	  2.	   Bondy,	  M.L.,	  Scheurer,	  M.E.,	  Malmer,	  B.,	  Barnholtz-­‐Sloan,	  J.S.,	  Davis,	  F.G.,	  Il'yasova,	  D.,	  Kruchko,	  C.,	  McCarthy,	  B.J.,	  Rajaraman,	  P.,	  Schwartzbaum,	  J.A.,	  et	  al.	  2008.	  Brain	  tumor	  epidemiology:	  consensus	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